ClinicalTrials.gg
TerminatedNCT02213042Updated Oct 13, 2021Results posted

Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

A Phase 2 interventional study of Lapatinib and Trastuzumab in Neoplasms, Breast, sponsored by Novartis Pharmaceuticals. Terminated at 51 sites in 12 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
Primary analysis was completed in 2018 and continued minimal data collection from the one participant active in the study was not expected to add meaningful knowledge to the understanding of lapatinib

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies testing lapatinib in Breast Neoplasms — none open to participants now, 3 under way, 1 of them phase 3. Lapatinib · Breast Neoplasms.

Enrollment
52nd of 114
42 · median 35
Started
2014
with 3 others
Phase 2
60 of 114
none open now
Registered
111th of 114
by date
Lead sponsor
15 of 114
Novartis Pharmaceuticals

Among the 114 studies testing lapatinib in Breast Neoplasms, this one is the 52nd largest by enrollment, is one of 4 that started in 2014, is one of 60 in phase 2, and was the 111th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 114 studies testing lapatinib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About lapatinib

Lapatinib: first FDA approval 2007 (TYKERB), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 114 studies testing lapatinib in Breast Neoplasms as a file.
02

Study summary

This was a multicenter, open-label, Phase II study in subjects with Human epidermal growth factor receptor (HER2)-positive metastatic breast cancer who received at least 2 prior lines of anti-HER2-targeted therapies of which at least one included a Trastuzumab-containing regimen. This study was a post-approval commitment with regulatory authorities. It was designed to evaluate whether treatment with Dual blockade promoted changes to biomarkers associated with immunomodulation.

Read the detailed description

This study was designed to address the post-authorization measures as agreed with the Committee for Medicinal Products for Human Use (CHMP). Recruitment of subjects into this study was challenging, and following agreement with the European Medicines Agency (EMA) enrollment into this study was halted after the enrollment of 42 of the 225 planned subjects.

The primary endpoint of the study evaluated changes in expression of biomarkers associated with immunomodulation between a pre-treatment biopsy and the disease progression biopsy. Secondary efficacy endpoints included overall response rate, clinical benefit rate and progression-free survival (PFS), as well as safety/tolerability. All subjects received study treatment until disease progression, death, unacceptable toxicity, or subject withdrawal. In case of disease progression during the treatment period, the subject was followed-up for 30 days for safety evaluation. In case of study treatment discontinuation for any reasons other than disease progression, the subject was followed-up for safety and efficacy assessments until disease progression, new anticancer therapy, death, withdrawal of consent or end of study, whichever came first.

This study supported a better understanding of the rapidly accumulating evidence for the importance of the immune microenvironment in HER2-positive breast cancer and the observed immunomodulation in the neoadjuvant setting could be confirmed in the advanced setting and supported the putative mechanism of action of HER2 dual blockade and its potential function on the tumor microenvironment. No formal comparisons between treatment arms were undertaken.

03

Conditions studied

  • Neoplasms, Breast

Browse trials for

Keywords

  • CLAP016A2206
  • biomarker
  • Lapatinib
  • Prosigna
  • ErbB2
  • PAM50
  • HER2
  • HER2-overexpressing metastatic breast cancer
  • HER2-enriched
  • Trastuzumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written
  • Female >=18 years
  • or cytologically confirmed invasive breast cancer with distant
  • Subjects must have at least one per 1.1
  • Note: Biopsied lesions should not be used as target lesions.
  • Documentation of overexpression or gene amplification, in the invasive component of either the primary tumor or metastatic disease site as defined as: 3+ by Immunohistochemistry (IHC) and/or
  • HER2/neu gene amplification by fluorescence, chromogenic, or silver in situ hybridization [FISH, CISH or SISH;>=6 HER2/neu gene copies per nucleus or a FISH, CISH, or SISH test ratio (HER2 gene copies to chromosome 17 signals) of >=2.0 OR HER2/chromosome 17 ratio \<=2.0 with average HER2 copy number >=6 signals/cell nucleus]
  • Centrally determined HER2-positive, hormone receptor status, breast molecular subtype by Prediction Analysis of Microarray 50 (PAM50) on the pre-treatment of metastatic lesion obtained during screening
  • Note: Biopsied lesions should not be used as target lesions.
  • Progression on at least 2 lines of anti-HER2-targeted therapies for metastatic breast cancer (MBC)
  • Documented radiological disease progression during the most recent treatment regimen for metastatic disease
  • Most recent treatment regimen for metastatic disease must include Trastuzumab and chemotherapy.
  • Note: Trastuzumab emtansine (T-DM1) is considered acceptable as prior Trastuzumab/chemotherapy regimen
  • Agreement to provide 2 tumor biopsies
  • Prior treatment with pertuzumab, Lapatinib, and/or Trastuzumab emtansine is allowed; however, the last treatment for MBC must not include Trastuzumab in combination with pertuzumab.
  • Subjects with radiographically stable Central nervous system (CNS) metastases, defined as radiographically stable on the previous 2 brain imaging scans, asymptomatic, and off systemic and anticonvulsants for at least 1 month are eligible; treatment with prophylactic anticonvulsants is permitted unless listed under Prohibited Medications
  • Discontinuation of all prior chemotherapy, immunotherapy, or biological therapy at least 3 weeks prior to the first dose of product is required.
  • Note: Discontinuation of Trastuzumab is not necessary.
  • All treatment related toxicities, except alopecia, must have recovered to Grade 1 or better ( (CTCAE); version 4.0) prior to administration of the first dose of study treatment.
  • Baseline (LVEF) >=50% as measured by Echocardiogram (ECHO) or Multigated acquisition (MUGA) and above the testing institution's lower limit of normal
  • corrected (QTc) \<450 millisecond (msec) or QTc \<480 msec for patients with bundle branch block.
  • The QTc is the QT interval corrected for heart rate according to either Bazett's formula (QTcB)
  • Fridericia's formula (QTcF), or another method, machine or manual overread.
  • For subject eligibility and withdrawal, QT correction formula QTcB will be used.
  • For purposes of this data analysis, Bazett's formula will be used as the primary method of calculating the corrected QT interval. The QTc should be based on either a single (ECG) or an average of 3 sequential ECGs obtained within 24 hours of each other.
  • The QTc should be based on single or averaged QTc values of triplicate ECGs obtained over a brief recording period.
  • Women of must have a negative serum pregnancy test within 7 days prior to the first dose of study treatment and agree to use effective , during the study and for 30 days following the last dose of study treatment.
  • (ECOG) performance status of 0 or 1
  • Completion of screening and baseline assessments
  • Able to swallow and retain orally administered medication and does not have any gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
  • At least 4 weeks must have elapsed since the last surgery and 2 weeks must have elapsed since radiotherapy
  • Adequate baseline organ function as defined below
  • Screening laboratory values should be used to confirm subject eligibility. Laboratory results may be retested if necessary to confirm eligibility.
  • Hematologic(These values must be independent of growth factor support and stable for at least one week post transfusion)
  • >=1.5 x 10\^9/litre (L)
  • >=9.0 grams/decilitre(g/dL) (after transfusion if needed)
  • >=100 x 10\^9/L
  • Hepatic
  • Albumin >=2.5 g/dL
  • Serum \<=1.25 x (ULN)( These values must be independent of growth factor support and stable for at least one week post transfusion)
  • ; and, Aspartate aminotransferase AST and ALT\<=2.5 x ULN
  • Renal
  • Calculate >=40 millilitre/ minute (mL/min) (With the exception of those subjects who have Gilbert's syndrome; the bilirubin in these subjects should be at their baseline)

Exclusion criteria

Exclusion Criteria:

  • Lactating female
  • Note: Women with potential to have children must be willing to practice acceptable methods of during the study
  • Bone-only disease and/or disease that cannot be biopsied.
  • Unstable or not considered radiographically stable
  • Note: Subjects with radiographically stable CNS metastases are defined as radiographically stable on the previous 2 brain imaging studies, asymptomatic, and off systemic and anticonvulsants for at least 1 month; treatment with prophylactic anticonvulsants is permitted unless listed under prohibited medications
  • Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions including concurrent disease that could interfere with subject's safety, obtaining , or compliance with the study procedures.
  • Serious cardiac illness or medical condition including but not confined to: Uncontrolled arrhythmias (e.g. ventricular tachycardia, high-grade atrioventricular (AV)-block, supraventricular arrhythmias which are not adequately rate-controlled);
  • Angina pectoris requiring antianginal medication
  • History of congestive heart failure or systolic dysfunction ( \<50%)
  • Documented myocardial infarction \<6 months from study entry
  • Evidence of transmural infarction on
  • Poorly controlled hypertension (e.g. systolic >160milimiter (mm) Mercury (Hg) or diastolic >100mm Hg)
  • valvular heart disease
  • Current active hepatic or biliary disease (with exception of subjects with Gilbert's syndrome, asymptomatic gallstones, liver , or stable chronic liver disease per investigator assessment)
  • Any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels as well as subjects with ulcerative colitis are also excluded
  • Any prohibited medication
  • Prior treatment with Trastuzumab in combination with Lapatinib or prior treatment with an irreversible inhibitor of the intracellular domain of the receptor such as neratinib
  • Last treatment for metastatic disease including Trastuzumab in combination with pertuzumab
  • Administration of an drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment
  • A known immediate or delayed reaction or idiosyncrasy to drugs chemically related to any of the study drugs or their that, in the opinion of the investigator or medical monitor, contraindicates participation
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Active comparator
    Lapatinib 1000mg + Trastuzumab in HER2 Enriched

    In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who were hormone receptor positive, an aromatase inhibitor of the investigator's choice was required.

    Drug: Lapatinib · Biological: Trastuzumab · Drug: Aromatase Inhibitors (AIs)

  • Active comparator
    Trastuzumab in HER2 Enriched

    In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Trastuzumab (loading dose of 8 mg/kg followed by the maintenance dose of 6 mg/kg IV q3weekly) along with chemotherapy of the investigator's choice or Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly along with chemotherapy of the investigators choice. Subjects randomized to this arm and hormone receptor positive received an aromatase inhibitor at the discretion of the investigator.

    Biological: Trastuzumab · Drug: Aromatase Inhibitors (AIs)

  • Active comparator
    Lapatinib 1000mg + Trastuzumab in Non- HER2 Enriched

    In subjects with HER2-overexpressing MBC with a molecular subtype of Non- HER2 Enriched (luminal A, luminal B or Basal type), Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who were hormone receptor positive, an aromatase inhibitor of the investigator's choice was required.

    Drug: Lapatinib · Biological: Trastuzumab · Drug: Aromatase Inhibitors (AIs)

Interventions

  • Lapatinib is available as 250-mg orange tablets. Subjects randomized to the Lapatinib plus Trastuzumab arm received 1000 mg per day of Lapatinib, so wre instructed to take 4 x 250 mg tablets per day. Lapatinib was to be taken either 1 hour (or more) before a meal or 1 hour (or more) after a meal

  • BiologicalTrastuzumab

    Trastuzumab is a sterile, white to pale yellow, preservative-free lyophilized powder for IV administration. Trastuzumab was administered on Day 1 of the start of Lapatinib or in conjunction with the first cycle of chemotherapy, as an 8 mg/kg loading dose. Subsequently, Trastuzumab was administered q3weekly as a 6 mg/kg maintenance dose. At the discretion of the investigator, weekly Trastuzumab could be given in either of the three treatment arms (loading dose 4mg/kg followed by weekly administration of 2mg/kg).

  • Subjects who were hormone receptor-positive were required to receive an aromatase inhibitor as combination treatment; however the choice of the aromatase inhibitor selected for each patient was determined by the patients' investigator. The AIs the Investigator could choose from were anastrozole, exemestane, and letrozole and dosing was per product information.

This study also gives Anastrozole, Exemestane. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Fold Change in Expression Profile of Genes and/or Proteins for Arm A (LAP+TRAS±AI (HER2-Enriched)) From Screening to Approx. 3.5 Years

    Evaluate changes in biomarkers associated with immunomodulation between pre-treatment biopsy and disease progression biopsy within each arm. Biomarker analysis was performed using an mRNA gene expression panel derived from Nanostring platform in a total of 20 subjects who received the study treatment as per the study design and with baseline tumor biopsies available. For the selected biomarkers associated with immunomodulation, the median fold changes of gene expression level and 95% confidence interval are presented. The fold change was calculated as the ratio of the expression level of a biomarker at disease progression over the baseline.

    Time frame: At screening and at disease progression, assessed up to approx. 3.5 years

  2. Fold Change in Expression Profile of Genes and /or Proteins for Arm B (TRAS+CHEM±AI (HER2-Enriched)) From Screening to Approx. 3.5 Years

    Evaluate changes in biomarkers associated with immunomodulation between pre-treatment biopsy and disease progression biopsy within each arm. Biomarker analysis was performed using an mRNA gene expression panel derived from Nanostring platform in a total of 20 subjects who received the study treatment as per the study design and with baseline tumor biopsies available. For the selected biomarkers associated with immunomodulation, the median fold changes of gene expression level and 95% confidence interval are presented. The fold change was calculated as the ratio of the expression level of a biomarker at disease progression over the baseline.

    Time frame: At screening and at disease progression, assessed up to approx. 3.5 years

  3. Fold Change in Expression Profile of Genes and /or Proteins for Arm C (Non-HER2- Enriched) From Screening to Approx. 3.5 Years

    Evaluate changes in biomarkers associated with immunomodulation between pre-treatment biopsy and disease progression biopsy within each arm. Biomarker analysis was performed using an mRNA gene expression panel derived from Nanostring platform in a total of 20 subjects who received the study treatment as per the study design and with baseline tumor biopsies available. For the selected biomarkers associated with immunomodulation, the median fold changes of gene expression level and 95% confidence interval are presented. The fold change was calculated as the ratio of the expression level of a biomarker at disease progression over the baseline.

    Time frame: At screening and at disease progression, assessed up to approx. 3.5 years

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as the time from the date of randomization (for Arm A and B) / treatment start date (for Arm C) to the date of the first documented disease progression or death due to any cause, whichever was earlier. If a subject had not progressed or died at the analysis cutoff date, PFS was censored at the time of the last adequate tumor assessment. PFS was summarized using Kaplan-Meier estimates.

    Time frame: From randomization to disease progression or death, up to approx. 5.6 years

  2. Overall Response Rate (ORR)

    Overall response rate was defined as the percentage of subjects achieving either a confirmed complete response (CR) or partial response (PR) and was calculated from the Investigator's assessment of response per RECIST 1.1 criteria. . The confirmed CR or PR was derived using the following rules: confirmed CR - at least two determinations of CR at least 4 weeks apart before disease progression; confirmed PR - at least two determinations of PR or better at least 4 weeks apart before progression.

    Time frame: From enrollment/randomization to the end of study, approximately 5.6 years

  3. Clinical Benefit Rate (CBR)

    CBR is defined as percentage of subjects with a complete response (CR), partial response (PR), or maintaining stable disease (SD) for at least 24 weeks while on study according to the investigator assessment of response per RECIST 1.1 criteria. CR and PR are confirmed responses derived using the following rules: Confirmed CR - at least 2 determinations of CR at least 4 weeks apart before disease progression. Confirmed PR - at least 2 determinations of PR or better at least 4 weeks apart before progression.

    Time frame: From enrollment/randomization the end of study, approximately 5.6 years

  4. Association Between Biomarkers and PFS

    Describe if changes of biomarker expression at disease progression from baseline correlate with PFS.

    Time frame: From randomization to disease progression or death, up to approx. 5.6 years

07

Results

Posted Sep 16, 2021

Participant flow

Overall, 225 subjects were planned and 42 subjects were enrolled in this study

Participant flow — Overall Study
MilestoneLAP+TRAS±AI (HER2-Enriched) - Arm ATRAS+CHEM±AI (HER2-Enriched) - Arm BNon-HER2- Enriched - Arm C
Started171510
Total deaths1196
Completed000
Not completed171510
Withdrew: Disease progression (incl. death due to disease progression)14138
Withdrew: Adverse event210
Withdrew: Withdrawal by subject011
Withdrew: Protocol violation100
Withdrew: Investigator discretion001

Outcome measures

PrimaryFold Change in Expression Profile of Genes and/or Proteins for Arm A (LAP+TRAS±AI (HER2-Enriched)) From Screening to Approx. 3.5 Years

Evaluate changes in biomarkers associated with immunomodulation between pre-treatment biopsy and disease progression biopsy within each arm. Biomarker analysis was performed using an mRNA gene expression panel derived from Nanostring platform in a total of 20 subjects who received the study treatment as per the study design and with baseline tumor biopsies available. For the selected biomarkers associated with immunomodulation, the median fold changes of gene expression level and 95% confidence interval are presented. The fold change was calculated as the ratio of the expression level of a biomarker at disease progression over the baseline.

Time frame:
At screening and at disease progression, assessed up to approx. 3.5 years
Reported as:
Median · Ratio of gene expression level
Fold Change in Expression Profile of Genes and/or Proteins for Arm A (LAP+TRAS±AI (HER2-Enriched)) From Screening to Approx. 3.5 Years
Ratio of gene expression levelLAP+TRAS±AI (HER2-Enriched) - Arm A
Membrane spanning 4-domains A10.25 (0.078 to 0.589)
POU class 2 associating factor 10.32 (0.183 to 0.543)
CD19+0.35 (0.106 to 0.904)
Interleukin 60.36 (0.033 to 0.832)
G antigen 10.43 (0.030 to 0.901)
ubiquitin specific peptidase 9, Y-linked0.50 (0.321 to 0.770)
Thy-1 cell surface antigen0.50 (0.113 to 0.902)
Chemerin chemokine-like receptor 10.51 (0.345 to 0.862)
Major histocompatibility complex, class II, DR beta 40.51 (0.320 to 0.984)
Collectin subfamily member 120.51 (0.151 to 0.794)
Complement C3b/C4b receptor 1 (Knops blood group)0.51 (0.227 to 0.901)
CD33 molecule0.56 (0.458 to 0.826)
B-cell linker0.56 (0.326 to 0.874)
Interleukin 12A0.57 (0.228 to 0.892)
CD163+0.57 (0.417 to 0.911)
C-C motif chemokine ligand 80.58 (0.138 to 0.954)
Chemokine (C-C motif) receptor 10.59 (0.501 to 0.792)
POU class 2 homeobox 20.60 (0.440 to 0.944)
Cyclin dependent kinase inhibitor 1A0.62 (0.453 to 0.873)
CD27 molecule0.62 (0.357 to 0.886)
Lymphocyte antigen 860.63 (0.383 to 0.906)
TNF superfamily member 80.64 (0.476 to 0.879)
CD34+0.67 (0.558 to 0.863)
Integrin subunit alpha 60.68 (0.470 to 0.827)
C-type lectin domain containing 7A0.69 (0.326 to 0.944)
CD180 molecule0.70 (0.347 to 0.869)
Integrin subunit alpha M0.72 (0.411 to 0.957)
Toll like receptor 60.72 (0.511 to 0.836)
Autophagy related 100.73 (0.662 to 0.864)
C-C motif chemokine ligand 3 like 10.74 (0.499 to 0.996)
Bone marrow stromal cell antigen 10.75 (0.345 to 0.922)
CD22+0.76 (0.629 to 0.936)
CD37 molecule0.76 (0.553 to 0.884)
NEG_A0.77 (0.674 to 0.949)
Sperm auto antigenic protein 170.79 (0.697 to 0.968)
CD200 molecule0.79 (0.598 to 0.945)
TNF receptor associated factor 30.82 (0.718 to 0.962)
Interferon alpha and beta receptor subunit 11.10 (1.036 to 1.124)
TNF receptor associated factor 61.21 (1.016 to 1.332)
PrimaryFold Change in Expression Profile of Genes and /or Proteins for Arm B (TRAS+CHEM±AI (HER2-Enriched)) From Screening to Approx. 3.5 Years

Evaluate changes in biomarkers associated with immunomodulation between pre-treatment biopsy and disease progression biopsy within each arm. Biomarker analysis was performed using an mRNA gene expression panel derived from Nanostring platform in a total of 20 subjects who received the study treatment as per the study design and with baseline tumor biopsies available. For the selected biomarkers associated with immunomodulation, the median fold changes of gene expression level and 95% confidence interval are presented. The fold change was calculated as the ratio of the expression level of a biomarker at disease progression over the baseline.

Time frame:
At screening and at disease progression, assessed up to approx. 3.5 years
Reported as:
Median · Ratio of gene expression level
Fold Change in Expression Profile of Genes and /or Proteins for Arm B (TRAS+CHEM±AI (HER2-Enriched)) From Screening to Approx. 3.5 Years
Ratio of gene expression levelTRAS+CHEM±AI (HER2-Enriched) - Arm B
C-type lectin domain containing 5A0.16 (0.020 to 0.440)
Interferon induced transmembrane protein 10.25 (0.183 to 0.421)
Fibronectin 10.27 (0.077 to 0.393)
C-C motif chemokine ligand 70.27 (-0.064 to 0.888)
Triggering receptor expressed on myeloid cells 10.27 (-0.018 to 0.959)
Plasminogen activator, urokinase0.27 (0.112 to 0.545)
Interleukin 22 receptor subunit alpha 20.28 (0.192 to 0.425)
C-C motif chemokine ligand 80.28 (0.044 to 0.699)
Tumor necrosis factor (ligand) superfamily member 4 gene0.31 (0.147 to 0.651)
Major histocompatibility complex, Class I-related0.32 (0.139 to 0.832)
Cathepsin L0.32 (0.066 to 0.820)
SPP-1 (Osteopontin)0.33 (0.076 to 0.501)
Thy-1 cell surface antigen0.34 (0.157 to 0.648)
Transforming growth factor beta 20.35 (0.120 to 0.504)
Hepatitis A virus cellular receptor 20.36 (0.138 to 0.614)
Bone marrow stromal cell antigen 10.37 (0.133 to 0.864)
C-type lectin domain containing 7A0.37 (0.166 to 0.570)
C-X-C motif chemokine ligand 50.38 (0.040 to 0.943)
Collagen type III alpha 1 chain0.40 (0.130 to 0.685)
Complement C1s0.41 (0.088 to 0.717)
IFIT1 gene0.41 (0.148 to 0.921)
Major histocompatibility complex, class I, G0.41 (0.147 to 0.698)
Tumour necrosis factor gene0.42 (0.108 to 0.945)
Integrin subunit beta 10.43 (0.231 to 0.864)
Pro-melanin concentrating hormone0.43 (0.081 to 0.972)
CD86+0.44 (0.102 to 0.700)
FCGR3A SNP rs3969910.44 (0.107 to 0.696)
TNF receptor superfamily member 10c0.44 (0.165 to 0.925)
Integrin subunit alpha M0.45 (0.166 to 0.797)
TNF receptor superfamily member 11b0.45 (0.114 to 0.923)
Platelet derived growth factor C0.45 (0.231 to 0.797)
Mannan binding lectin serine peptidase 10.46 (0.304 to 0.896)
Recombination activating 10.46 (0.394 to 0.597)
Interleukin 220.47 (0.229 to 0.609)
Tumor necrosis factor (ligand) superfamily member 13b gene0.47 (0.179 to 0.697)
BMI1 proto-oncogene, polycomb ring finger0.47 (0.322 to 0.735)
CXCL10 gene0.48 (0.074 to 0.986)
Leukocyte immunoglobulin like receptor B10.48 (0.142 to 0.747)
MX1 gene0.48 (0.155 to 0.781)
Tumor necrosis factor (ligand) superfamily member 11 gene0.48 (0.227 to 0.798)
Cathepsin S0.49 (0.138 to 0.807)
Interferon induced transmembrane protein 20.49 (0.245 to 0.887)
LYN proto-oncogene, Src family tyrosine kinase0.50 (0.360 to 0.685)
Platelet derived growth factor receptor beta0.50 (0.160 to 0.801)
OAS3 gene0.50 (0.284 to 0.899)
CD58 molecule0.50 (0.398 to 0.619)
complement C3a receptor 10.51 (0.147 to 0.949)
Chemokine (C-C motif) receptor 10.52 (0.159 to 0.815)
Interleukin 24 gene0.52 (0.161 to 0.706)
Chemokine (C-X-C motif) receptor 20.53 (0.295 to 0.629)
Strawberry notch homolog 21.13 (1.045 to 1.300)
Zinc finger protein 2051.42 (1.144 to 1.815)
Fas associated via death domain1.58 (1.107 to 2.043)
CD3e molecule associated protein1.67 (1.244 to 2.075)
Baculoviral IAP repeat containing 51.73 (1.003 to 2.635)
Interleukin 17 receptor B2.01 (1.151 to 2.975)
PrimaryFold Change in Expression Profile of Genes and /or Proteins for Arm C (Non-HER2- Enriched) From Screening to Approx. 3.5 Years

Evaluate changes in biomarkers associated with immunomodulation between pre-treatment biopsy and disease progression biopsy within each arm. Biomarker analysis was performed using an mRNA gene expression panel derived from Nanostring platform in a total of 20 subjects who received the study treatment as per the study design and with baseline tumor biopsies available. For the selected biomarkers associated with immunomodulation, the median fold changes of gene expression level and 95% confidence interval are presented. The fold change was calculated as the ratio of the expression level of a biomarker at disease progression over the baseline.

Time frame:
At screening and at disease progression, assessed up to approx. 3.5 years
Reported as:
Median · Ratio of gene expression level
Fold Change in Expression Profile of Genes and /or Proteins for Arm C (Non-HER2- Enriched) From Screening to Approx. 3.5 Years
Ratio of gene expression levelNon-HER2- Enriched - Arm C
Triggering receptor expressed on myeloid cells 10.50 (0.294 to 0.995)
Interleukin 1 receptor, type 1 gene1.58 (1.235 to 2.328)
Complement component 22.13 (1.011 to 3.567)
Coagulation factor XII2.69 (1.062 to 4.229)
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from the date of randomization (for Arm A and B) / treatment start date (for Arm C) to the date of the first documented disease progression or death due to any cause, whichever was earlier. If a subject had not progressed or died at the analysis cutoff date, PFS was censored at the time of the last adequate tumor assessment. PFS was summarized using Kaplan-Meier estimates.

Time frame:
From randomization to disease progression or death, up to approx. 5.6 years
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsLAP+TRAS±AI (HER2-Enriched) - Arm ATRAS+CHEM±AI (HER2-Enriched) - Arm BNon-HER2- Enriched - Arm C
Progression-free Survival (PFS)6.0 (2.10 to 10.60)7.2 (2.10 to 14.80)6.0 (1.60 to 8.30)
SecondaryOverall Response Rate (ORR)

Overall response rate was defined as the percentage of subjects achieving either a confirmed complete response (CR) or partial response (PR) and was calculated from the Investigator's assessment of response per RECIST 1.1 criteria. . The confirmed CR or PR was derived using the following rules: confirmed CR - at least two determinations of CR at least 4 weeks apart before disease progression; confirmed PR - at least two determinations of PR or better at least 4 weeks apart before progression.

Time frame:
From enrollment/randomization to the end of study, approximately 5.6 years
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsLAP+TRAS±AI (HER2-Enriched) - Arm ATRAS+CHEM±AI (HER2-Enriched) - Arm BNon-HER2- Enriched - Arm C
Overall Response Rate (ORR)35.3 (14.2 to 61.7)33.3 (11.8 to 61.6)30.0 (6.7 to 65.3)
SecondaryClinical Benefit Rate (CBR)

CBR is defined as percentage of subjects with a complete response (CR), partial response (PR), or maintaining stable disease (SD) for at least 24 weeks while on study according to the investigator assessment of response per RECIST 1.1 criteria. CR and PR are confirmed responses derived using the following rules: Confirmed CR - at least 2 determinations of CR at least 4 weeks apart before disease progression. Confirmed PR - at least 2 determinations of PR or better at least 4 weeks apart before progression.

Time frame:
From enrollment/randomization the end of study, approximately 5.6 years
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR)
Percentage of participantsLAP+TRAS±AI (HER2-Enriched) - Arm ATRAS+CHEM±AI (HER2-Enriched) - Arm BNon-HER2- Enriched - Arm C
Clinical Benefit Rate (CBR)35.3 (14.2 to 61.7)46.7 (21.3 to 73.4)30.0 (6.7 to 65.3)
SecondaryAssociation Between Biomarkers and PFS

Describe if changes of biomarker expression at disease progression from baseline correlate with PFS.

Time frame:
From randomization to disease progression or death, up to approx. 5.6 years

No measurements were reported for this outcome.

Post-hocAll-Collected Deaths

On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 168 weeks for Lapatinib, (treatment duration ranged from 151 to 164 weeks), 164 weeks for Trastuzumab (treatment duration ranged from 0 to 160 weeks), 168 weeks for Aromatase Inhibitors (treatment duration ranged from 9 to 164 weeks). Deaths post treatment survival follow up were collected after the on- treatment period, up to approx. 5.6 years.

Time frame:
On-treatment deaths: up to approx. 168 weeks, Total deaths: up to approx. 5.6 years
Reported as:
Number · Participants
All-Collected Deaths
ParticipantsLAP+TRAS±AI (HER2-Enriched) - Arm ATRAS+CHEM±AI (HER2-Enriched) - Arm BNon-HER2- Enriched - Arm C
Total Deaths1196
On-treatment deaths310

Adverse events

Collected over On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 168 weeks for lapatinib, for a maximum duration of 164 weeks for trastuzumab and for a maximum duration of 168 weeks for aromatase inhibitors (anastrozole, letrozole and exemestane.). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LAP+TRAS±AI (HER2-Enriched) - Arm A3/17 (17.6%)1/17 (5.9%)15/17 (88.2%)
TRAS+CHEM±AI (HER2-Enriched) • ArmB1/15 (6.7%)1/15 (6.7%)14/15 (93.3%)
Non-HER2-Enriched - Arm C0/10 (0%)2/10 (20%)10/10 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventLAP+TRAS±AI (HER2-Enriched) - Arm ATRAS+CHEM±AI (HER2-Enriched) • ArmBNon-HER2-Enriched - Arm C
SeizureNervous system disorders0/170/151/10
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/170/151/10
Breast neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/171/150/10
Cardiac arrestCardiac disorders1/170/150/10
Escherichia sepsisInfections and infestations1/170/150/10
SepsisInfections and infestations1/170/150/10
Urinary tract infectionInfections and infestations1/170/150/10
HypoalbuminaemiaMetabolism and nutrition disorders1/170/150/10
HypoglycaemiaMetabolism and nutrition disorders1/170/150/10
HypokalaemiaMetabolism and nutrition disorders1/170/150/10
Most frequent other events
Showing 10 of 79
Most frequent other events
EventLAP+TRAS±AI (HER2-Enriched) - Arm ATRAS+CHEM±AI (HER2-Enriched) • ArmBNon-HER2-Enriched - Arm C
DiarrhoeaGastrointestinal disorders9/171/156/10
VomitingGastrointestinal disorders1/171/154/10
NauseaGastrointestinal disorders1/175/153/10
Alanine aminotransferase increasedInvestigations0/175/150/10
AlopeciaSkin and subcutaneous tissue disorders0/175/150/10
Decreased appetiteMetabolism and nutrition disorders2/170/153/10
NeutropeniaBlood and lymphatic system disorders1/174/150/10
AstheniaGeneral disorders3/174/152/10
ParonychiaInfections and infestations4/170/150/10
AnaemiaBlood and lymphatic system disorders2/173/152/10

Baseline characteristics

Full Analysis Set (FAS): Consisted of all subjects who were randomized to study Arm A or Arm B or assigned to study Arm C, irrespective of whether they actually received study treatment.

Age, Customized
Age, Customized(Participants)LAP+TRAS±AI (HER2-Enriched) - Arm ATRAS+CHEM±AI (HER2-Enriched) - Arm BNon-HER2- Enriched - Arm CTotal
< 65 years1415635
>= 65 years3047
Sex: Female, Male
Sex: Female, Male(Participants)LAP+TRAS±AI (HER2-Enriched) - Arm ATRAS+CHEM±AI (HER2-Enriched) - Arm BNon-HER2- Enriched - Arm CTotal
Female17151042
Male0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)LAP+TRAS±AI (HER2-Enriched) - Arm ATRAS+CHEM±AI (HER2-Enriched) - Arm BNon-HER2- Enriched - Arm CTotal
Caucasian14111035
African American1203
Asian1203
Native Hawaiian or Pacific Islander1001
08

Study locations

51 sites
  • Novartis Investigative Site
    Mobile, Alabama 36608, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02114, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Berazategui, Buenos Aires B1880BBF, Argentina
  • Novartis Investigative Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1125ABD, Argentina
  • Novartis Investigative Site
    Viedma, Río Negro R8500ACE, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe S2000KZE, Argentina
  • Novartis Investigative Site
    Ciudad Autonoma de Buenos Aires, C1025ABI, Argentina
  • Novartis Investigative Site
    Cordoba, X5004FHP, Argentina
  • Novartis Investigative Site
    La Rioja, F5300COE, Argentina
  • Novartis Investigative Site
    San Miguel de Tucuman, T4000IAK, Argentina
  • Novartis Investigative Site
    Salzburg, A-5020, Austria
  • Novartis Investigative Site
    Wien, 1090, Austria
  • Novartis Investigative Site
    Salvador, Bahía 41825-010, Brazil
  • Novartis Investigative Site
    Belo Horizonte, Minas Gerais 30130-090, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande Do Sul 90430-090, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande Do Sul 90470-340, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande Do Sul 90610-000, Brazil
  • Novartis Investigative Site
    Itajai, Santa Catarina 88301220, Brazil
  • Novartis Investigative Site
    Barretos, São Paulo 14784-400, Brazil
  • Novartis Investigative Site
    Sao Paulo, São Paulo 01236030, Brazil
  • Novartis Investigative Site
    Sao Paulo, São Paulo 01317-001, Brazil
  • Novartis Investigative Site
    Sao Jose do Rio Preto, 15090-000, Brazil
  • Novartis Investigative Site
    Pok Fu Lam, Hong Kong
  • Novartis Investigative Site
    Pokfulam, Hong Kong
  • Novartis Investigative Site
    Milano, Lombardia 20133, Italy
  • Novartis Investigative Site
    Milano, Lombardia 20141, Italy
  • Novartis Investigative Site
    Mexico, 06760, Mexico
  • Novartis Investigative Site
    Arequipa, Peru
  • Novartis Investigative Site
    Lima, Lima 34, Peru
  • Novartis Investigative Site
    Cebu, 6000, Philippines
  • Novartis Investigative Site
    Manila, 1000, Philippines
  • Novartis Investigative Site
    Kazan, 420029, Russian Federation
  • Novartis Investigative Site
    Moscow, 115 478, Russian Federation
  • Novartis Investigative Site
    Ryazan, 390011, Russian Federation
  • Novartis Investigative Site
    St. Petersburg, 197022, Russian Federation
  • Novartis Investigative Site
    St. Petersburg, 197758, Russian Federation
  • Novartis Investigative Site
    Volzhskiy, 404130, Russian Federation
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Barcelona, 08036, Spain
  • Novartis Investigative Site
    Donostia, 20014, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Madrid, 28040, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Malaga, 29010, Spain
  • Novartis Investigative Site
    Sevilla, 41013, Spain
  • Novartis Investigative Site
    Valencia, 46010, Spain
  • Novartis Investigative Site
    Valencia, 46015, Spain
  • Novartis Investigative Site
    Bangkok, 10330, Thailand
  • Novartis Investigative Site
    Chiangmai, 50200, Thailand
  • Novartis Investigative Site
    Phitsanulok, 65000, Thailand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in Jun 2020, 67 months.

Results were first posted in Sep 2021, 1 year 3 months after primary completion. A results delay was requested in May 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2014
First posted
Aug 11, 2014
StartActual
Oct 24, 2014
Primary completionActual
Jun 4, 2020
CompletionActual
Jun 4, 2020
Results delay requested
May 3, 2021
Results first posted
Sep 16, 2021
Last update
Oct 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02213042
Responsible party
Sponsor
First posted
Aug 11, 2014
Start date
Oct 24, 2014
Primary completion
Jun 4, 2020
Completion
Jun 4, 2020
Results posted
Sep 16, 2021
Last update
Oct 13, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lapatinib · Trastuzumab

Start the discussion